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A Ab bs st tr ra ac ct t    Serological markers are key elements in diagnosing acute hepatitis B virus 
(HBV) infection and determining its possible evolution towards chronicity. 
Once treatment of chronic HBV is initiated with approved anti-hepadnaviral 
agents, such as lamivudine, interferon-alpha, or adefovir dipivoxil, the 
measurement of HBV DNA in serum can not only help monitor treatment 
efficacy but also indicates breakthrough infection should drug resistance 
emerge. Advances in the molecular diagnosis of drug resistance using highly 
sensitive methodologies such as DNA hybridization assays can further 
pinpoint the type of mutation responsible and, more importantly, detect 
upcoming viral resistance at an early stage when the variant represents only a 
minor fraction of the total viral population. Such new tools are especially 
relevant for patients at high risk for disease progression or acute 
exacerbation. Recent diagnostic developments including HBV genotyping 
and precore/core promoter assays that could well play important future roles 
in HBV patient management are also reviewed.  
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1.  From Acute to Chronic HBV Disease 
When hepatitis B virus (HBV) infection is suspected, it is the appearance of serum markers of HBV infection that establishes 
the diagnosis of the disease. Of these, HBsAg is considered to be the sentinel marker for the confirmation of acute infection. Its 
presence can be detected as early as 6 weeks after exposure, and should therefore be assessed when prodromal (malaise, anorexia, 
fever, rash, arthralgia) or more classical symptoms (dark urine, jaundice) are observed. Generally, some 8 to 16 weeks will usually 
have elapsed from exposure to the virus until the appearance of telltale symptoms. HBsAg is also the key marker in determining 
whether hepatitis B infection has become chronic: defined as the persistence of the surface antigen for at least 6 months [1]. By 
contrast, if acute disease resolves, HBsAg declines followed by a subsequent rise of antibodies to the surface antigen (anti-HBs) 
upon recovery (Figure 1).  
Serum HBV DNA and HBeAg are two other key markers appearing precociously, and are indicative of active viral replication. 
The former may be present at levels exceeding 10
5 to 10
6 copies/mL and can be identified some 6-12 weeks after exposure to the 
virus, or even earlier if PCR-based methods are used. During acute infection, HBeAg and transaminase levels are also elevated. As 
the immune system begins to mount its response to infection, an initial rise - then decline - of anti-HBc IgM, is observed. By 
contrast, anti-HBc IgG rises but persists even after acute infection has resolved.  As HBV viremia is cleared, anti-HBe also begins to 
increase, and alanine aminotransferase (ALT) levels decline [2]. 
Of the two billion persons worldwide who come into contact with HBV, approximately 6% of the global population (more than 
350 million persons) fail to resolve acute viral infection and become chronic carriers, eventually placing between 15% to 25% of 
such individuals at risk for end-stage liver disease. Should chronic carriage ensue, those persons who are unable to resolve HBV 
infection enter into a low replication phase of infection marked by the seroconversion of HBeAg to anti-HBe. This change occurs in 
about 10% (5%-20%) of chronic adult carriers per year [3]. The inactive carrier state is marked by continued HBsAg positivity, in 
contrast to a drop in HBV DNA levels to less than 10
5 copies/mL. In addition, ALT levels and anti-HBc IgM decline and normalize; 
liver histology shows a significant reduction in necro-inflammation. Sometimes the passage to this phase is marked by a flare-up in 
disease activity termed seroconversion illness [2]. Repeated episodes of active hepatitis may occur until final anti-HBe 
seroconversion materializes. 
This classical course of events may be confounded by several exceptions. For instance, core promoter or precore mutations lead 
to HBV variants that either drastically curtail or abolish HBeAg production, respectively. As seroconversion to anti-HBe progresses 
(ie HBeAg-expressing variants are eliminated immunologically, while precore variants escape detection, survive, and increase), 
circulating levels of HBV DNA remain high and liver disease persists or relapses [4]. 
Moreover, the age when infection is acquired markedly influences the course of disease. Three predominant patterns have been 
noted: (i) early (perinatal) infection – especially prevalent in Asia and Oceania – characterized by a long immune tolerant phase 
(high serum HBV DNA, persistent HBeAg positivity, normal ALT, poor response to therapy); (ii) person-to-person HBV 
transmission in childhood frequently observed in sub-Saharan Africa, the Mediterranean countries, and Alaska where such children 
exhibit HBeAg-positivity, elevated ALT, and peripubertal seroconversion to anti-HBe; and (iii) acquisition of HBV during 
adulthood as often happens among persons in Western countries with an absence of immune tolerance, a relatively rapid progression 
to immune clearance, and a better response to therapy [1].  
2.  Relevance and Utility of HBV DNA Detection Methods 
Although HBV DNA assays are not presently recommended for the routine evaluation and management of patients with 
chronic HBV infections, they nevertheless provide very useful adjunct information concerning viral replication – especially in 
situations when patient serological profiles fall outside of classical patterns. Some key advantages and disadvantages of HBV DNA 
testing are presented in Table 1.  
Current HBV DNA assays make use of differing technologies and can generally be divided into (i) signal amplification assays 
(liquid phase hybridization, antibody capture approach, branched DNA) and (ii) DNA amplification tests based on the polymerase 
chain reaction (PCR) [for detailed reviews, see 2,5].  Signal amplification assays have sensitivities approaching 1 pg of DNA (10
5-
10
6 genome copies) or even to 10
3 genome copies [2].  Alternatively, HBV DNA detection based on a nested PCR approach can 
detect as few as 10
2-10
3 genome copies. At such low titers, problems with contamination and reproducibility may lead to false-
positive results, thereby necessitating the use of internal or external standards [5]. Commercial assays that make use of semi-
automated systems can overcome these limitations [2,5].  
In contrast to PCR tests that measure HBV DNA titers only after completion of the PCR cycle (‘endpoint measurement’), real-
time PCR technology, based on continuous quantitative monitoring during the exponential phase of the PCR reaction, is able to 
measure viral loads over a larger dynamic range [2,5]. New developments (TaqMan technology, molecular beacons) that decrease 
the number of handling steps, reduce contamination, and increase throughput and the accuracy of quantification will further enhance 
the utility of these assays [2,5].  
Given the varied technologies used to determine HBV DNA titers, it is understandable that considerable variation in results 
may occur when using different viral load tests. This makes standardization of HBV DNA viral load assays an important issue that is 
yet to be resolved [2]. Collaborative studies have been undertaken to establish international standards for HBV DNA nucleic acid 
amplification techniques [5,6], but no clear consensus has yet emerged. Finally, the role of viral load testing to detect drug resistance 
is discussed below. 
3.  HBV Treatment Options and Drug Resistance 
For the 350 million persons chronically infected with HBV, the two therapeutic approaches presently available to control 
infection and its sequelae are immunomodulatory agents and/or antiviral chemotherapy. Such treatments aim at interrupting the 
progression and clinical outcomes of the disease (cirrhosis, hepatocellular carcinoma) by stimulating the anti-HBV-specific host 
immune response or by markedly decreasing viral replication. Int. J. Med. Sci. 2005 2(1) 
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The first therapeutic agent to be approved for hepatitis B was interferon-alpha (IFN-α), whose dual mode of action includes 
both  antiviral and immunomodulatory effects. Unfortunately, extended IFN-α treatment is expensive, injection-dependent, effective 
in no more than 15-25% of patients, and associated with a wide spectrum of adverse reactions [7]. These limitations will be partially 
obviated by the likely approval of peginterferon-alpha for use in chronic HBV. One recent phase 2, dose-ranging study indicated that 
the once-weekly dose of this agent resulted in a two-fold higher response rate (HBeAg seroconversion; HBV suppression, ALT 
normalization) after six months of treatment compared to conventional interferon, although the frequencies of adverse events were 
similar [8]. 
However, it is the nucleoside analogue lamivudine that has become the gold standard worldwide for use in patients with chronic 
hepatitis B. The convenience of its relatively affordable cost, a one-pill-per-day regimen, and the low incidence of side effects has 
made it the preferred treatment for many patients. Nevertheless, despite a good safety profile and initial efficacy, lamivudine-
induced decreases in viral load are difficult to sustain over time due to the occurrence of viral drug resistance. Thus, the antiviral 
effects of the drug are gradually reversed in most cases. The ensuing rebound effect [9,10] is termed breakthrough infection. It is 
now known that genotypic resistance to lamivudine emerges in approximately one quarter of patients after one year of treatment [11-
13], rising to more than 40% after two years, and increasing further to over 50% and 70% after years three and four, respectively 
[13]. Increasing the drug dosage does not appear to substantially affect the rate at which viral resistance occurs [11]. 
The armamentarium of HBV therapy has recently been expanded by the approval of the nucleotide analog, adefovir dipivoxil. 
Its antiviral efficacy was confirmed in large-scale clinical trials for the therapy of both HBeAg-positive [14] and HBeAg-negative 
[15] chronic hepatitis B, achieving more than a 3-log decrease in viral load, a significant drop in serum ALT levels, and an 
improvement in liver histology after one to two years of therapy. Although resistance surveillance in adefovir-treated patients for 
potential resistance mutations until 48 weeks [16] and then up to 60 weeks [17] did not reveal the emergence of resistant mutants, 
this did not turn out to be the case upon treatment after 96 weeks [18]. Just as is the present case for lamivudine, resistance testing 
for adefovir mutations could become necessary should the rate of emergence of resistance and the impact of such mutations turn out 
to be clinically relevant for therapy management.   
4.  Molecular Mechanisms of Drug Resistance 
HBV is a small but elusive DNA virus that presents relatively few specific targets for antiviral interventions. At present, the 
target of choice is the HBV polymerase protein – an enzyme that plays an essential role in viral replication [19]. Within its four 
functional regions (Figure 2), drug resistance to lamivudine is associated with mutations in the very conserved catalytic polymerase 
/reverse transcriptase domain of the gene [20], located specifically at a locus of four amino acids consisting of tyrosine-methionine-
aspartate-aspartate, termed the YMDD motif [21]. It is thought that lamivudine acts here by suppressing HBV replication. Given that 
HBV generates up to 10
12 virions/day [22], and because of the selective pressure exerted by long-term administration of lamivudine 
on the virus, HBV mutants emerge.  
When mutations occur, the configuration of the wild-type YMDD motif becomes altered in such a way that the drug no longer 
successfully exerts its inhibitory action at that site. Both wild-type and resistance virus strains then populate the infected liver. HBV 
DNA and ALT levels usually begin to rebound, but are generally lower compared to baseline levels when only wild-type virus is 
present.  
Three key mutations in the polymerase gene have been shown to confer resistance to lamivudine and adefovir dipivoxil (Figure 
2), although many other mutations have also been described [19]. With respect to the recently adopted nomenclature for HBV 
mutations in the polymerase region [23], the first two include the substitution of methionine (M) by the amino acids isoleucine (I) or 
valine (V) in the YMDD motif (C domain) at position rtM204V/I. In the majority of cases, these mutations in the YMDD motif 
occur together with an additional compensatory mutation in the B subdomain [20], namely the substitution of a leucine by 
methionine some 20 amino acids upstream from the YMDD domain at position rtL180M. Finally, the newly discovered mutant to 
adefovir (rtN236T) is located downstream from the YMDD motif in the D domain of the viral polymerase. 
Assuming correct patient compliance with treatment, resistance to antiviral therapy is presently defined as (i) an increase in 
serum HBV DNA titers during therapy after a sustained viral response and (ii) the selection of a mutation in the viral polymerase 
gene (YMDD motif of the polymerase C domain) that could not be detected in the major viral species prior to therapy, and that is 
not included in the HBV consensus sequences from data banks (i.e., genotypic resistance) [24]. 
5.  Monitoring HBV Drug Resistance 
Several options are currently available to monitor HBV drug resistance, and can generally be divided into genotypic assays and 
phenotypic methods. The former detect changes in the HBV genomic sequence in the course of treatment. In addition, indirect 
measures of lamivudine resistance including determination of ALT values, and especially HBV DNA (viral load) assays are 
routinely used in the clinic. A comparison of these methods is presented in Table 2. 
(1) Genotyping Methods 
Direct DNA Sequencing 
Standard DNA sequencing technology provides highly accurate and complete DNA sequence information, and is applicable to 
any part of the 3.2-kilobase HBV genome [25]. A serious handicap is the inability of sequencing to detect viral resistance even when 
the mutated virus still makes up a relatively large fraction (up to 30%) of the entire HBV population (i.e., mixtures of wild-type and 
mutant species). This limits its use for detecting upcoming resistance at an early stage [26]. Furthermore, it tends to be time-
consuming and labor intensive, not readily adaptable to high-throughput screening, and is amenable to analysis only by well-trained 
personnel. Int. J. Med. Sci. 2005 2(1) 
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Clonal Analysis 
An additional difficulty when using direct DNA sequencing of a PCR product is to know whether a given set of mutations 
occurs on the same molecule or in a different clonal subpopulation. This obstacle can theoretically be circumvented by sequencing 
multiple clones from a given sample. But unless a sufficient amount of clones are analyzed, minor subpopulations may remain 
undetected [20,27]. The technique is quite laborious, and is not adaptable for large-scale use. 
RFLP 
This methodology provides a means of overcoming some of the aforementioned limitations. RFLP methodology is as accurate 
as direct DNA sequencing [28] but, unlike sequencing, can detect samples with mixed virus populations containing mutant virus 
making up 5% to 10% of the virus population [29,30]. Nevertheless, the procedure is generally long and tedious (multiple PCRs, 
multiple enzyme digestions), and requires skilled personnel since a specific endonuclease reaction has to be developed for each 
separate mutation to be analyzed. Such tests tend to be ‘home brews,’ and have not been commercialized for general use [28,31]. 
DNA Hybridization 
Various types of assays exist that make use of probe-product hybrids. For instance, fluorometric real-time PCR with the 
LightCycler Assay can be used to detect resistant variants. Samples differing by only one nucleotide can be readily distinguished 
[32,33]. However, natural sequence variability in places where the fluorescence probes bind can lead to a lower melting temperature 
of the probe without necessarily being associated with a resistance mutation. Moreover, for unequivocal detection of lamivudine 
resistance, the variant subpopulation may have to comprise at least 5% to 10% of the total [33].  Another test that employs mixed 
hybridization-sequencing-PCR (“minisequencing”) technology involves the extension of multiple oligonucleotide primers with 
fluorescent ddNTPs by means of a DNA polymerase [34]. 
An alternative approach involves differential hybridization to a preexisting panel of membrane-bound probes as illustrated by 
the commercially available INNO-LiPA HBV DR line probe assay (Figure 3). The test makes use of a series of short immobilized 
oligonucleotide probes to discriminate between different nucleic acid fragments (down to single nucleotide mismatches), thereby 
enabling identification of wild-type or mutant variants [23,26]. Importantly, the test can detect variations early during the emergence 
of viral resistance even when the variant represents only a minor fraction of the total viral population [26,35]. This is especially 
relevant for patients at high risk for disease progression. An example of the monitoring and early detection of HBV drug resistance 
with this test is shown in Figure 4. In the consecutive patient samples presented, the YIDD mutation (rtM204I) was detected about 
40 weeks after the start of lamivudine therapy, some 10 and twelve weeks before the increases in viral load and ALT, respectively. 
Subsequently, the YIDD mutation was replaced by a YVDD mutant. This latter mutation was seen to persist (over 40 weeks) after 
lamivudine treatment was halted. 
The limitation of such hybridization-based methods (melting curve analysis, line probe assays) lies in their single-base 
discrimination. Specificity can be influenced by the sequences neighboring a polymorphic site, or by possible interference from 
secondary structures [36]. Furthermore, as new mutations arise, such hybridization-based assays must be updated accordingly.  
Recent Developments 
Possible future methods for detection of resistance could make use of technologies such as fluorescence (relying on secondary 
reporter systems) [37,38] or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) 
[39,40]. They offer a highly sensitive means to detect unidentified HBV variants – even when comprising only a small percentage of 
wild-type/mutant mixtures. While fast and accurate, these methods require the use of well-trained technicians and expensive 
equipment, and have not been optimized for high-throughput use.  
Oligonucleotide Microarrays 
Microchip-based tests can also be envisaged for HBV resistance testing, as they may be well suited for the study of multiple 
mutations on the same genome [41]. However, as the number of clinically relevant mutants is presently relatively limited, the 
development of microarray-based assays for HBV resistance will probably not be cost effective unless combined with other tests. 
(2) Indirect Methods 
Quantification of HBV DNA (viral load assays) 
Aside from its role as a ‘baseline’ indicator of HBV infectivity, the measurement of viral load is an indispensable means for 
monitoring and confirming resistance to lamivudine therapy. Indeed, resistance to antivirals is still generally defined clinically by a 
rise in serum HBV DNA levels during antiviral therapy.  
Although HBV DNA assays will eventually detect changes in viral load as a consequence of emerging resistance to lamivudine 
(see further), other factors (e.g., compliance) may also be responsible for alterations in HBV DNA levels. Therefore, viral load 
measurements and changes in ALT titers should, by themselves, not be solely relied upon as indicators of viral resistance now that 
specific genotyping tests for drug resistance are available. Moreover, when a given mutation represents only a minor fraction of the 
total viral population, viral load will only be proportionately affected, and will rise with a variable delay with respect to the onset 
and progression of resistance (Figure 4). Therefore, the combined use of a genotyping assay for polymerase mutant detection and 
quantitative detection of viremia with a highly sensitive assay is warranted for optimal monitoring of HBV antiviral therapy [42,43].  Int. J. Med. Sci. 2005 2(1) 
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(3) Phenotyping Methods 
These methods detect drug resistance based on the use of molecular or cellular techniques or using animal models [20]. Such 
systems are useful for studying HBV replication, cellular accumulation of covalently closed circular DNA, and for characterizing 
HBV mutants. However, their use is labor-intensive and not amenable to high-throughput testing or commercialization. 
6.  Management of HBV Drug Resistance 
Given the recent approval of adefovir dipivoxil, and the probability that other antivirals could also become available in the not-
too-distant future, the management of drug resistance must now be seen within a broadening and evolving clinical context. 
Moreover, it is increasingly apparent that clinically relevant prediction and monitoring of viral resistance may not only require the 
use of existing tools such as drug resistance and viral load testing, but might also have to be extended to include the detection of 
mutations in the precore and core promoter regions as well as HBV genotyping. This is because recent studies have, for instance, 
shown that patients with precore mutants who develop lamivudine resistance may have a higher risk for severe exacerbation of liver 
disease [44,45]. This is especially worrying since chronic HBV patients harbouring precore mutants generally require long-term 
therapy.  Numerous studies also indicate strong associations between certain viral genotypes that influence mutational patterns in the 
precore/core promoter regions responsible for either abolishing or diminishing HBeAg production [46,47].  
7.  Clinical Impact of Hepatitis B Genotypes 
For a DNA virus, the HBV genome shows an exceptional degree of molecular variation (incorporation of some 10
10 mistaken 
nucleotides into the HBV virion per day [21]). Over time, this spontaneous tendency for mutations has led to the emergence of at 
least seven HBV genotypes (designated A to G), defined by a divergence of 8% or more with reference to the complete nucleotide 
sequence. These different genotypes show a distinct geographic distribution: genotype A is found in northern Europe, the United 
States, and Central Africa; B and C predominate in Asia; D is associated with southern Europe, the Middle East, and India; E is 
uniquely African; and F is found in Central and South America as well as in Polynesia [48,49]. Genotype G has recently been 
localized in the United States and France [50], while a putative eighth genotype H has also been discovered in Central America [51]. 
The study of possible clinical ramifications of HBV genotypes is the subject of intense clinical research, with evidence accumulating 
that HBV genotyping influences the natural history and severity of liver disease, HBeAg seroconversion rates, precore/core 
promoter mutational patterns, and response to treatment (Table 3). Its determination – just as is the case for hepatitis C – could well 
emerge as an important consideration in the clinical evaluation of HBV patients prior to treatment.  
8.  Research Directions 
Advances in HBV diagnostic testing have fortuitously paralleled the advent of new, effective drugs for HBV that have already 
been, or will soon be approved in the near future. These new assays - combined with classical diagnostic methods - will help 
determine the best long-term treatment strategies (sequential, combined, etc.) for the use of such new drugs. At the same time, a key 
challenge is the integration of HBV diagnostic testing with new therapeutic agents in order to ensure optimized, tailored patient 
treatment. Such integrated HBV diagnostic and treatment strategies will undoubtedly have to be adapted to economic imperatives 
and epidemiological realities (geographic patterns and modes of transmission). For instance, this implies differing testing-treatment 
schemes depending on whether high-incidence, less affluent regions or low-incidence, high-affluent areas are being targeted. 
Whatever the strategies that emerge, both classical HBV serological tests and advanced molecular diagnostics will be used together 
to monitor therapeutic efficacy and ensure cost-effectiveness.   
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Tables and Figures 
Table 1. Advantages and disadvantages of HBV DNA testing 
Advantages Disadvantages 
Earliest indicator of infectivity  Definitive role in patient management still to be clarified 
Can help monitor effectiveness of antiviral therapy Not  yet  recommended for routine evaluation 
Can help assess ongoing disease activity in chronic infections  Not well standardized 
Can indicate and confirm emergence of antiviral resistance  Wide variation in test sensitivities 
Direct marker and gold standard for HBV viral replication  No gold standard among different methodologies 
Useful marker of infectivity in presence of precore/core promoter 
mutants 
Relatively slower to detect drug resistance 
Confirmation of spontaneous remission or co-infection  Detection of low viral levels of uncertain clinical significance 
  Cut-off levels for inactive disease unclear 
  Threshold levels for progressive liver disease unknown 
Table 2. Comparison of different commercial and non-commercial testing methods for detection of drug resistance. 
 
 
Sensitivity1/ 
Early detection 
Information 
content2 
Updateability3 Commercial 
availability 
Cost Complexity  of 
interpretation 
Labor 
intensiveness 
Automatability 
Genotypic 
Methods 
            
Direct  
Sequencing 
15-50% high  high  yes  high high  Intermediate 
high 
yes 
RFLP 5-10%  low  low  no  low  intermediate  high  no 
RT-PCR 5-10%  low  low  no  high  intermediate  low  no 
LiPA 5%  low  low-intermediate  yes  intermediate  low  low  yes 
Florescence  nd  intermediate  intermediate  no  intermediate intermediate intermediate  yes 
MALDI-TOF  <5%  intermediate  intermediate  No  intermediate intermediate intermediate  yes 
DNA arrays  na  intermediate  intermediate  no  high  high  low  yes 
Indirect 
methods 
            
Viral load  na  na  na  yes  intermediate  low  low  yes 
Phenotypic 
Assays 
na  na  low  no  high high high  no 
1Sensitivity here refers to the lowest level (%) at which an assay can detect mixtures of mutant and wild-type virus. 
2Information content is 
considered as a measure of a test’s ability to provide broad, relevant information about possible new mutations. 
3Updateability assesses the ease at 
which a test can be adapted to incorporate the detection of a new mutation. na, not applicable. nd, not determined. Int. J. Med. Sci. 2005 2(1) 
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Table 3. Emerging clinical relevance of genotyping 
Characteristic  Country and Reference  Comment 
Hong Kong , Yuen et al. [52]  Earlier with genotype B than with C 
Taiwan, Kao et al. [53]  Earlier with genotype B than with C 
Japan,  Sumi et al. [54]  Earlier with genotype B than with C 
HBeAg seroconversion 
United States,  Chu et al. [55]  Earlier with genotype B than with C 
Hong Kong, Chan et al. [56]  More active liver disease with C than B 
Taiwan, Kao et al. [57]  More severe disease with C incl. more HCC 
Japan, Duong et al. [58]  More chronic liver disease with C  vs. asymptomatic 
with  D + earlier seroconversion 
Japan, Sumi et al. [54]  Slower development of liver fibrosis and HCC with 
genotype B than with C 
India,  Thakur et al. [59]  More severe liver disease with D than A 
Disease progression 
(natural history) 
Spain, Sanchez-Tapias et al. [60]  More deaths and severe disease outcome with F than 
with A or D 
Hong Kong, Yuen et al. [61]  Rates to lamivudine same for B and C 
Taiwan, Kao et al. [57]  Rates to lamivudine same for B and C 
Japan, Sumi et al. [54]  More core promoter mutants with C than B 
Development of 
mutations 
East Asia, Lindh et al. [46]  More core promoter mutants with C + more severe 
liver disease 
Taiwan ,Kao et al. [57]  Better response with genotype B than C 
Japan, Seo et al. [62]  Better response with genotype B than C 
Response to interferon-
alpha 
U.S.,  Wai et al. [63]  More HBeAg clearance with B than C 
Taiwan, Kao et al. [57]  Better virological response with B than C  Response to lamivudine 
Taiwan, Chien et al. [64]  More sustained response woth B than C 
Figure 1. Evolution of HBV markers in acute and chronic infection.  
 
Figure 2. Key HBV polymerase mutants resistant to lamivudine (LMV) and adefovir dipivoxil (ADV). The HBV polymerase 
can be divided into four functional regions. Of these, the reverse transcription region (RT), responsible for RNA- and DNA-
dependent DNA synthesis contains seven motifs (A thru G).  
 Int. J. Med. Sci. 2005 2(1) 
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Figure 3.  Example of line probe assay (LiPA) 
detection system based on the reverse 
hybridization principle. Such line probe assays 
make use of a series of short, immobilized 
oligonucleotides attached as parallel lines on 
nitrocellulose membrane strips, permitting easy 
identification of wild-type virus or mutant variants. 
For this purpose, biotinylated, amplified viral DNA 
fragments derived from hepatitis B patients are 
hybridized to the selected immobilized probes. 
Streptavidin labeled with alkaline phosphatase is then 
added, and binds to the previously formed 
biotinylated hybrids. Incubation with a chromogen 
results in color development. After amplification, 
such a test takes less than 2.5 hours to perform. 
 
 
Figure 4. Example of patient follow-up showing the 
development of drug resistance as monitored by the 
INNO-LiPA HBV DR assay. For details, see text. 
Case history courtesy of HG Niesters (Dept. of 
Virology, University Medical Center, Rotterdam, The 
Netherlands). 
 